Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
about
MicroRNA and Heart FailureSacubitril/valsartan in heart failure: latest evidence and place in therapyRare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal PolyneuropathiesProteases Revisited: Roles and Therapeutic Implications in Fibrosis.Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.Neprilysin and Natriuretic Peptide Regulation in Heart Failure.Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HFNeprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.The need to apply the best therapy in heart failure - the era after PARADIGM-HF.Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure.Recent advances in point-of-care testing for natriuretic peptides: potential impact on heart failure diagnosis and management.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels.Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients.A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
P2860
Q26750638-4BEA9F1B-8326-40FF-B2E6-019F0F0F3973Q28070191-11D0FC69-D2FB-49C1-97FB-8CE1CFEBD3C3Q28114961-8D874682-9BDD-4EFD-8F34-B038686D09B0Q33795055-1E3CF28D-EA3B-40A5-87F2-9FF4F60FD8BCQ38754215-3155E7EB-44F8-4CBD-A2D4-7C0F31114430Q38853482-9EFC8427-5304-4303-A6F0-0507F656EFF3Q38854043-3D56679B-1AEF-46A8-A2B2-42582C20D4D5Q38857852-88153886-F45F-438A-AA37-BB22C094552DQ39011741-C59466D3-FCFD-4498-9993-ACD646A39F2EQ39192295-06628314-37A9-4632-997E-5ECEA5E15DC5Q40149965-EB5919ED-5EAD-4F42-8865-6847B31685EAQ41083010-1EF25F89-B85F-4A33-9BEF-EB8BCBA99C3CQ41549509-8D48E239-E6CA-4723-B266-91152659BF0CQ41628214-F8452532-2CCD-4C0C-B033-6A3AE681122FQ46335976-7B759A6B-7A39-4404-9B5D-8E66A4EB2CABQ47855200-67DAB299-9E59-4844-A82E-E6C245B03EE3Q48547451-3E43C0A4-EA50-4489-B499-9D08EB12AC80Q51252064-A67CF317-FDEA-4394-8CEB-40D0B28BBC74Q58796491-DD488716-B784-4B82-9271-C9B4EB7BC61B
P2860
Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Soluble neprilysin is predicti ...... ion in heart failure patients.
@en
Soluble neprilysin is predicti ...... ion in heart failure patients.
@nl
type
label
Soluble neprilysin is predicti ...... ion in heart failure patients.
@en
Soluble neprilysin is predicti ...... ion in heart failure patients.
@nl
prefLabel
Soluble neprilysin is predicti ...... ion in heart failure patients.
@en
Soluble neprilysin is predicti ...... ion in heart failure patients.
@nl
P2093
P50
P1476
Soluble neprilysin is predicti ...... tion in heart failure patients
@en
P2093
Agustín Urrutia
Amparo Galán
Mar Domingo
Marta de Antonio
P304
P356
10.1016/J.JACC.2014.11.048
P407
P577
2015-02-01T00:00:00Z